CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial

CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial

A reliable biomarker (e.g. CA-125) that could both monitor the course of the illness and identify disease progression to permit effective intervention to prevent symptoms and prolong survival would be useful in the management of ovarian cancer. But will somewhat earlier detection of disease recurren...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology 2010-01, Vol.78 (1), p.1-2
Hauptverfasser: Markman, Maurie, Petersen, Judith, Belland, Angela, Burg, Kenda
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Biomarkers, Tumor - blood
CA-125 Antigen - blood
Editorial
Female
Health Care Surveys
Humans
Monitoring systems
Mortality
Ovarian cancer
Ovarian Neoplasms - blood
Ovarian Neoplasms - diagnosis
Randomized Controlled Trials as Topic
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2
container_issue 1
container_start_page 1
container_title Oncology
container_volume 78
creator Markman, Maurie
Petersen, Judith
Belland, Angela
Burg, Kenda
description A reliable biomarker (e.g. CA-125) that could both monitor the course of the illness and identify disease progression to permit effective intervention to prevent symptoms and prolong survival would be useful in the management of ovarian cancer. But will somewhat earlier detection of disease recurrence actually improve outcome?
doi_str_mv 10.1159/000292352
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733789442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733789442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-d2f1dab288bbafbb9ddc69cde885010ccca94e02bf6cd5b3f5c81c905ff11d903</originalsourceid><addsrcrecordid>eNpdkU1PwkAQhjdGI4gevBuz8WI8VPajS7veSIMfCQSDeG62210sli7uthj-vS1FTDxNZvLMk8k7AFxidI8x432EEOGEMnIEutgn1EOEkmPQRYgij_jY74Az55Y1FjB_cAo6BBHMgpB0wXc09DBhcGKKrDQ2KxYwK-B0I2wmChiJQir7AF9FmamihG-V3agtnCm3NoVTDpYGlh-qGVR56aDRu3Yyi_qj6Wwewb19t5fleaOD81qdn4MTLXKnLva1B94fR_Po2RtPn16i4diTlJLSS4nGqUhIGCaJ0EnC01QOuExVGDKEkZRScF8hkuiBTFlCNZMhlhwxrTFOOaI9cNt619Z8VcqV8SpzUjWnKFO5OKA0CLlfh9YDN__IpalsUR8XDwgP6sTCRnfXQtIa56zS8dpmK2G3MUZx84v48Iuavd4Lq2Sl0gP5G34NXLXAp7ALZf-Adv8HFB-LAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>629702180</pqid></control><display><type>article</type><title>CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial</title><source>Karger Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Markman, Maurie ; Petersen, Judith ; Belland, Angela ; Burg, Kenda</creator><creatorcontrib>Markman, Maurie ; Petersen, Judith ; Belland, Angela ; Burg, Kenda</creatorcontrib><description>A reliable biomarker (e.g. CA-125) that could both monitor the course of the illness and identify disease progression to permit effective intervention to prevent symptoms and prolong survival would be useful in the management of ovarian cancer. But will somewhat earlier detection of disease recurrence actually improve outcome?</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000292352</identifier><identifier>PMID: 20215782</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Biomarkers ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; Editorial ; Female ; Health Care Surveys ; Humans ; Monitoring systems ; Mortality ; Ovarian cancer ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Randomized Controlled Trials as Topic</subject><ispartof>Oncology, 2010-01, Vol.78 (1), p.1-2</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>Copyright (c) 2010 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-d2f1dab288bbafbb9ddc69cde885010ccca94e02bf6cd5b3f5c81c905ff11d903</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20215782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Markman, Maurie</creatorcontrib><creatorcontrib>Petersen, Judith</creatorcontrib><creatorcontrib>Belland, Angela</creatorcontrib><creatorcontrib>Burg, Kenda</creatorcontrib><title>CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial</title><title>Oncology</title><addtitle>Oncology</addtitle><description>A reliable biomarker (e.g. CA-125) that could both monitor the course of the illness and identify disease progression to permit effective intervention to prevent symptoms and prolong survival would be useful in the management of ovarian cancer. But will somewhat earlier detection of disease recurrence actually improve outcome?</description><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>Editorial</subject><subject>Female</subject><subject>Health Care Surveys</subject><subject>Humans</subject><subject>Monitoring systems</subject><subject>Mortality</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1PwkAQhjdGI4gevBuz8WI8VPajS7veSIMfCQSDeG62210sli7uthj-vS1FTDxNZvLMk8k7AFxidI8x432EEOGEMnIEutgn1EOEkmPQRYgij_jY74Az55Y1FjB_cAo6BBHMgpB0wXc09DBhcGKKrDQ2KxYwK-B0I2wmChiJQir7AF9FmamihG-V3agtnCm3NoVTDpYGlh-qGVR56aDRu3Yyi_qj6Wwewb19t5fleaOD81qdn4MTLXKnLva1B94fR_Po2RtPn16i4diTlJLSS4nGqUhIGCaJ0EnC01QOuExVGDKEkZRScF8hkuiBTFlCNZMhlhwxrTFOOaI9cNt619Z8VcqV8SpzUjWnKFO5OKA0CLlfh9YDN__IpalsUR8XDwgP6sTCRnfXQtIa56zS8dpmK2G3MUZx84v48Iuavd4Lq2Sl0gP5G34NXLXAp7ALZf-Adv8HFB-LAQ</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Markman, Maurie</creator><creator>Petersen, Judith</creator><creator>Belland, Angela</creator><creator>Burg, Kenda</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial</title><author>Markman, Maurie ; Petersen, Judith ; Belland, Angela ; Burg, Kenda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-d2f1dab288bbafbb9ddc69cde885010ccca94e02bf6cd5b3f5c81c905ff11d903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>Editorial</topic><topic>Female</topic><topic>Health Care Surveys</topic><topic>Humans</topic><topic>Monitoring systems</topic><topic>Mortality</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markman, Maurie</creatorcontrib><creatorcontrib>Petersen, Judith</creatorcontrib><creatorcontrib>Belland, Angela</creatorcontrib><creatorcontrib>Burg, Kenda</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markman, Maurie</au><au>Petersen, Judith</au><au>Belland, Angela</au><au>Burg, Kenda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>78</volume><issue>1</issue><spage>1</spage><epage>2</epage><pages>1-2</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>A reliable biomarker (e.g. CA-125) that could both monitor the course of the illness and identify disease progression to permit effective intervention to prevent symptoms and prolong survival would be useful in the management of ovarian cancer. But will somewhat earlier detection of disease recurrence actually improve outcome?</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>20215782</pmid><doi>10.1159/000292352</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0030-2414
ispartof Oncology, 2010-01, Vol.78 (1), p.1-2
issn 0030-2414
1423-0232
language eng
recordid cdi_proquest_miscellaneous_733789442
source Karger Journals; MEDLINE; Alma/SFX Local Collection
subjects Biomarkers
Biomarkers, Tumor - blood
CA-125 Antigen - blood
Editorial
Female
Health Care Surveys
Humans
Monitoring systems
Mortality
Ovarian cancer
Ovarian Neoplasms - blood
Ovarian Neoplasms - diagnosis
Randomized Controlled Trials as Topic
title CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CA-125%20Monitoring%20in%20Ovarian%20Cancer:%20Patient%20Survey%20Responses%20to%20the%20Results%20of%20the%20MRC/EORTC%20CA-125%20Surveillance%20Trial&rft.jtitle=Oncology&rft.au=Markman,%20Maurie&rft.date=2010-01-01&rft.volume=78&rft.issue=1&rft.spage=1&rft.epage=2&rft.pages=1-2&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000292352&rft_dat=%3Cproquest_pubme%3E733789442%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=629702180&rft_id=info:pmid/20215782&rfr_iscdi=true